Islet Cell TumorNCT00830557
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
An observational study of Islet Cell Tumor and Pancreatic Cancer, run by Mayo Clinic at 3 sites in United States.
Trial summary
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease
- What is being tested?
- medical chart review, survey administration and biospecimen collection
- How many people
- 20,000 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Oct 2000to 30 Aug 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with known or suspected pancreas disease including pancreas adenocarcinoma, islet cell cancer, pancreatic cysts, pancreatitis (hereditary, acute, or chronic) or the next of kin of deceased participants.
Who may be able to join
None listed.
Who cannot join
- Under the age of 18
- Unable to provide informed consent
- Prison inmates
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
Pancreas Team, 904-953-6970, pancreas@mayo.edu
Michael Wallace, MD
- Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054
Pancreas Team, 480-301-8000, pancreas@mayo.edu
Zhi Fong, MD
- Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Pancreas Team, 800-914-7962, pancreas@mayo.edu
Shounak Majumder, MD
About this study
Official title: Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.
PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.
Read the detailed description
PRIMARY OBJECTIVE:
- To maintain a resource (bank) of biospecimens and data collected from individuals being seen clinically for pancreas conditions to facilitate the discovery and development of (but not limited to) biomarkers of risk (including genomic and proteomic) and early detection as well as novel targeted therapies for pancreatic diseases with a focus on pancreatic cancer.
OUTLINE: This is an observational study.
Patients undergo blood, saliva, and previously obtained leftover tissue sample collection on study. Patients also complete questionnaires and have their medical records reviewed on study.
- Conditions
- Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis
- Being tested
- medical chart review, survey administration, biospecimen collection
- Keywords
- recurrent pancreatic cancer, stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent islet cell carcinoma, pancreatic alpha cell carcinoma, pancreatic beta islet cell carcinoma, pancreatic delta cell carcinoma, pancreatic G-cell carcinoma
- Medical subject headings
- Adenoma, Islet Cell, Pancreatic Neoplasms, Pancreatic Diseases, Pancreatitis, Pancreatitis, Chronic, Hereditary pancreatitis, Somatostatinoma, Carcinoma, Islet Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
medical chart reviewOther
baseline, 12 month and 36 months
survey administrationOther
baseline, 6 month, 12 month
biospecimen collectionOther
baseline
| Study group | Role | What they receive |
|---|---|---|
| Observational | Patients undergo blood, saliva, and previously obtained leftover tissue sample collection on study. Patients also complete questionnaires and have their medical records reviewed on study. Receives: Other: medical chart review; Other: survey administration; Other: biospecimen collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Collection of clinical data, health and family histories by survey
Measured: baseline enrollment, 6 months, 12 months
Collection of blood and/or tissue, fecal and oral specimens
Measured: baseline
Collection of information regarding food preparation and intake by survey
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2009 (estimated)
- Study start1 Oct 2000
- Primary completion30 Aug 2027 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Islet Cell TumorStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Shounak Majumder, Mayo Clinic
- Investigators
- Shounak Majumder, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00830557
- Sponsor's protocol ID
- 354-06
- Other IDs
- P50CA102701, CDR0000613100, U01CA210138
- Status last verified
- Mar 2026
- First submitted
- 27 Jan 2009
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease
- ClinicalTrials.gov ID
- NCT00830557
- Acronym / sponsor ID
- 354-06
- Conditions
- Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis
- Keywords
- recurrent pancreatic cancer, stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent islet cell carcinoma, pancreatic alpha cell carcinoma, pancreatic beta islet cell carcinoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 1 Oct 2000 (actual)
- Primary completion
- 30 Aug 2027 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 28 Jan 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.
PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.
Detailed description
PRIMARY OBJECTIVE:
- To maintain a resource (bank) of biospecimens and data collected from individuals being seen clinically for pancreas conditions to facilitate the discovery and development of (but not limited to) biomarkers of risk (including genomic and proteomic) and early detection as well as novel targeted therapies for pancreatic diseases with a focus on pancreatic cancer.
OUTLINE: This is an observational study.
Patients undergo blood, saliva, and previously obtained leftover tissue sample collection on study. Patients also complete questionnaires and have their medical records reviewed on study.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: medical chart review, Other: survey administration, Other: biospecimen collectionPatients undergo blood, saliva, and previously obtained leftover tissue sample collection on study. Patients also complete questionnaires and have their medical records reviewed on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with known or suspected pancreas disease including pancreas adenocarcinoma, islet cell cancer, pancreatic cysts, pancreatitis (hereditary, acute, or chronic) or the next of kin of deceased participants.
Key inclusion criteria (0 listed)
Key exclusion criteria (3 listed)
- Under the age of 18
- Unable to provide informed consent
- Prison inmates
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| medical chart reviewbaseline, 12 month and 36 months | Other | Observational |
| survey administrationbaseline, 6 month, 12 month | Other | Observational |
| biospecimen collectionbaseline | Other | Observational |
Primary outcome
Collection of clinical data, health and family histories by survey
Time frame: baseline enrollment, 6 months, 12 months
Collection of blood and/or tissue, fecal and oral specimens
Time frame: baseline
Collection of information regarding food preparation and intake by survey
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Islet Cell Tumor
RecruitingPhase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruitingPhase 2
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
RecruitingPhase 2/3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer, Renal Cell Carcinoma (RCC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shounak Majumder, MD principal investigator
Mayo Clinic
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Islet Cell Tumor and Pancreatic Cancer, run by Mayo Clinic at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Adriana Delgado, MA (800-914-7962, pancreas@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Collection of clinical data, health and family histories by survey (time frame: baseline enrollment, 6 months, 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.